AnaptysBio Inc
NASDAQ:ANAB

Watchlist Manager
AnaptysBio Inc Logo
AnaptysBio Inc
NASDAQ:ANAB
Watchlist
Price: 44.35 USD 2.42% Market Closed
Market Cap: 1.2B USD

AnaptysBio Inc
PP&E Net

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

AnaptysBio Inc
PP&E Net Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company PP&E Net CAGR 3Y CAGR 5Y CAGR 10Y
AnaptysBio Inc
NASDAQ:ANAB
PP&E Net
$14.5m
CAGR 3-Years
-11%
CAGR 5-Years
43%
CAGR 10-Years
38%
Abbvie Inc
NYSE:ABBV
PP&E Net
$5.5B
CAGR 3-Years
4%
CAGR 5-Years
2%
CAGR 10-Years
8%
Gilead Sciences Inc
NASDAQ:GILD
PP&E Net
$5.5B
CAGR 3-Years
1%
CAGR 5-Years
3%
CAGR 10-Years
10%
Amgen Inc
NASDAQ:AMGN
PP&E Net
$7.2B
CAGR 3-Years
12%
CAGR 5-Years
8%
CAGR 10-Years
4%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
PP&E Net
$3B
CAGR 3-Years
27%
CAGR 5-Years
27%
CAGR 10-Years
16%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
PP&E Net
$5B
CAGR 3-Years
11%
CAGR 5-Years
10%
CAGR 10-Years
13%
No Stocks Found

AnaptysBio Inc
Glance View

Market Cap
1.2B USD
Industry
Biotechnology

AnaptysBio, Inc. is a clinical stage biotechnology company. The company is headquartered in San Diego, California and currently employs 102 full-time employees. The company went IPO on 2017-01-26. The firm is focused on the immune control mechanisms applicable to inflammation and immuno-oncology indications. The company develops products using antibody discovery technology platform, which is based upon a natural process of antibody generation, known as somatic hypermutation, and replicates this natural process of antibody generation in vitro. Its advanced antibody programs include: Imsidolimab is an antibody that inhibits the interleukin-36 receptor, for the treatment of inflammatory diseases called generalized pustular psoriasis and hidradenitis suppurativa; Rosnilimab is an anti-PD-1 agonist antibody program, is designed to augment PD-1 signaling through Rosnilimab treatment to suppress T-cell driven human inflammatory diseases; anti-BTLA modulator antibody, known as ANB032, is applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation.

ANAB Intrinsic Value
48.62 USD
Undervaluation 9%
Intrinsic Value
Price

See Also

What is AnaptysBio Inc's PP&E Net?
PP&E Net
14.5m USD

Based on the financial report for Sep 30, 2025, AnaptysBio Inc's PP&E Net amounts to 14.5m USD.

What is AnaptysBio Inc's PP&E Net growth rate?
PP&E Net CAGR 10Y
38%

Over the last year, the PP&E Net growth was -13%. The average annual PP&E Net growth rates for AnaptysBio Inc have been -11% over the past three years , 43% over the past five years , and 38% over the past ten years .

Back to Top